{"code":"SASDW54","status":"Published","type_of_curve":"SEC-SAS","angular_unit":"1/A","project":{"title":" <scp>IgG4</scp>\n              and <scp>IgG1</scp>\n              undergo common acid‐induced compaction into an alternatively folded state","publication":{"title":" <scp>IgG4</scp>\n              and <scp>IgG1</scp>\n              undergo common acid‐induced compaction into an alternatively folded state","author_list":"Imamura H, Honda S","journal":"FEBS Letters","doi":"10.1002/1873-3468.70031","pmid":null,"published_date":"2025 Mar 17"},"status":"released","submitted_date":"2024-12-19","released_date":"2025-03-17"},"pddf_data":"https://www.sasbdb.org/media/p_of_R_files/SASDW54.out","intensities_data":"https://www.sasbdb.org/media/intensities_files/SASDW54.dat","intensities_log_plot":"https://www.sasbdb.org/media/intensities_files/scattering_plots/SASDW54_dat_img.png","intensities_kratky_plot":"https://www.sasbdb.org/media/intensities_files/scattering_plots/SASDW54_kratky_img.png","pddf_plot":"https://www.sasbdb.org/media/p_of_R_files/pofr_images/SASDW54_pofr_img.png","intensities_guinier_plot":"https://www.sasbdb.org/media/intensities_files/scattering_plots/SASDW54_guinier_img.png","sascif_data":"https://www.sasbdb.org/media/sascif/sascif_files/SASDW54.sascif","experiment":{"instrument":{"detector":{"type":null,"name":"Pilatus3 2M","resolution":0.172},"name":"Photon Factory (PF), High Energy Accelerator Research Organization (KEK)","city":"Tsukuba","country":"Japan","beamline_name":"BL-10C","beam_geometry":null,"type_of_source":"X-ray synchrotron","point_source":null,"line_collimation":null,"sample_path_length":null,"line_collimation_slitlength":null,"line_collimation_integrationwidth":null,"xray_energy":null,"beam_profile_ah":null,"beam_profile_al":null},"sample":{"molecule":[{"long_name":"humanized immunoglobulin G1 monoclonal antibody (trastuzumab)","short_name":"IgG1","sequence":">Heavy chain 1\r\nEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY\r\nADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS\r\nASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS\r\nGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG\r\nPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN\r\nSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE\r\nMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW\r\nQQGNVFSCSVMHEALHNHYTQKSLSLSPGK\r\n>Heavy chain 2\r\nEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY\r\nADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS\r\nASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS\r\nGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG\r\nPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN\r\nSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE\r\nMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW\r\nQQGNVFSCSVMHEALHNHYTQKSLSLSPGK\r\n>Light chain 1\r\nDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS\r\nRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP\r\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\r\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC\r\n>Light chain 2\r\nDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS\r\nRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP\r\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\r\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","organism":"Mouse/human","uniprot_code":null,"uniprot_range_first":null,"uniprot_range_last":null,"oligomerization":"monomer","molecular_type":"protein","uniprot_sequence":"","mw":148.0,"total_mw":148.0,"number_molecules":1,"complex_state":false,"deuteration":null,"molecule_source":"biological","molecule_description":"DrugBank ID: DB00072\r\nhttps://go.drugbank.com/drugs/DB00072\r\nHeavy chains' C-terminal K residues are deleted for Herceptin (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan), commercially available trastuzumab, according to the information in PMDA (Pharmaceuticals and Medical Devices Agency): Review report regarding the anti-HER2 humanized monoclonal antibody Herceptin® Injection 60 and 150, on Jan. 16th 2008 (https://www.pmda.go.jp/drugs/2007/P200700066/45004500_21300AMY00128_A100_2.pdf)."}],"buffer":{"name":"100 mM glycine-HCl, 200 mM NaCl","concentration_unit":null,"comment":null,"additive":null,"concentration":null,"pka":null,"ph":2.0,"deuteration":null},"purity_method":null,"name":"Immunoglobulin G1 (pH 2, 0.2 M NaCl), SEC-SAXS data","ext_coefficient":null,"contrast":null,"specific_vol":null,"dry_vol":null,"absorbption":null,"deuteration":null,"mixture":null},"contributor":[{"affiliation":[{"short_name":null,"address":null,"full_name":"Toyama Prefectural University","webpage":null}],"contributor_name":"Hiroshi","contributor_surname":"Imamura","orcid":"https://orcid.org/0000-0001-8924-747X"}],"concentration_method":null,"concentration_unit":null,"date":"2023-05-20","storage_temperature":4.0,"cell_temperature":25.0,"exposure_time":20.0,"number_of_frames":13,"wavelength":0.15,"sample_detector_distance":2.0,"concentration_min":null,"concentration_max":10.0,"sample_volume":400.0,"flow_rate":0.2,"s_min":0.044,"s_max":2.731,"total_exposure_time":null,"seccolumn":1},"fits":[],"estimated_volume_method":null,"pddf_software":"ATSAS GNOM","pddf_software_version":"5.0","i0_calibration_standard":null,"description":"DrugBank ID: DB00072 https://go.drugbank.com/drugs/DB00072. Heavy chains' C-terminal K residues are deleted for Herceptin (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan), commercially available trastuzumab, according to the information in PMDA (Pharmaceuticals and Medical Devices Agency): Review report regarding the anti-HER2 humanized monoclonal antibody Herceptin® Injection 60 and 150, on Jan. 16th 2008 (https://www.pmda.go.jp/drugs/2007/P200700066/45004500_21300AMY00128_A100_2.pdf).","experiment_description":"Synchrotron SAXS data from solutions of Immunoglobulin G in 100 mM glycine-HCl, 200 mM NaCl, pH 2 were collected on the BL-10C beam line at the Photon Factory High Energy Accelerator Research Organization (KEK; Tsukuba, Japan) using a Pilatus3 2M detector at a sample-detector distance of 2 m and at a wavelength of λ = 0.15 nm (I(s) vs s, where s = 4πsinθ/λ, and 2θ is the scattering angle). In-line size-exclusion chromatography (SEC) SAS was employed. The SEC parameters were as follows: A 400.00 μl sample at 10 mg/ml was injected at a 0.20 ml/min flow rate onto a GE Superdex 200 Increase 10/300 column at 25°C. 13 successive 20 second frames were collected. The data were normalized to the intensity of the transmitted beam and radially averaged; the scattering of the solvent-blank was subtracted.","tags":[],"intensity_unit":"1/cm","experimental_mw":131.0,"experimental_mw_error":null,"guinier_i0_mw":131.0,"guinier_i0_mw_error":0.2,"porod_mw":150.0,"porod_mw_error":null,"pddf_i0":0.09482,"pddf_i0_error":null,"guinier_i0":0.0956356,"guinier_i0_error":null,"pddf_rg":4.17,"pddf_rg_error":null,"guinier_rg":4.184,"guinier_rg_error":0.169,"pddf_dmax":12.85,"pddf_dmax_error":null,"porod_volume":240.0,"porod_volume_error":null,"estimated_volume":null,"estimated_volume_error":null,"guinier_point_first":60,"guinier_point_last":231,"pddf_point_first":null,"pddf_point_last":null,"i0_calibration_standard_data":null,"intensities_log_log_plot":"SASDW54_datloglog_img.png","symmetry":null,"last_modified":"2025-03-17T16:06:56.010203+01:00","bragg_peak":[]}